Strength	1 mg
Pack Type	Prefilled Pen
Volume	3 ml
Brand	novo nordisk
Usage	Weight Loss
Storage Temp	2–8°C
Shelf Life	24 months

Wegovy 1mg (semaglutide) is a prescription injection for chronic weight management, mimicking the GLP-1 hormone to reduce appetite, increase fullness, and slow digestion, requiring a reduced-calorie diet and exercise; it's for adults/adolescents with obesity or overweight with related conditions, and helps lower cardiovascular risk, administered once weekly via subcutaneous injection (abdomen, thigh, upper arm) using a pre-filled FlexTouch pen, with common side effects including nausea and diarrhea, and contraindications for certain thyroid cancers (MTC) or MEN 2. What it is:

• Active Ingredient: Semaglutide, a GLP-1 receptor agonist.
• Form: A once-weekly subcutaneous (under the skin) injection, often in a pre-filled FlexTouch pen. 

How it Works:

• Mimics the natural GLP-1 hormone, regulating appetite and food intake.
• Activates brain receptors to make you feel full (satiated).
• Slows down how quickly food leaves the stomach (gastric emptying).
• Results in reduced hunger and lower calorie consumption. 

Who it's For:

• Adults and adolescents (12+) with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition (like high blood pressure, Type 2 diabetes, high cholesterol).
• Adults with obesity/overweight and established cardiovascular disease to reduce heart attack, stroke, and cardiovascular death risk. 

Usage:

• Once weekly injection in the abdomen, thigh, or upper arm.
• Used with a reduced-calorie diet and increased physical activity. 

Key Points:

• Not a quick fix: Part of a long-term weight management plan.
• Common Side Effects: Nausea, diarrhea, vomiting, constipation, stomach pain.

Additional Information:

• Packaging Details: 1*1

Brand	Mounjaro
Strength	7.5 MG/0.6 ML
Pack Size	1 prefilled pen
Delivery Form	Prefilled Pen
Application	Type 2 Diabetes, Weight Management
Prescription Type	Rx Only
Storage Temperature	2–8°C
Shelf Life	36 months
Usage	Human Use
Country Of Origin	India

Mounjaro 7.5 mg is a once-weekly, self-administered subcutaneous injection containing tirzepatide, designed to improve glycemic control in adults with type 2 diabetes and aid in weight management. It works as a dual GIP and GLP-1 receptor agonist to enhance insulin secretion, slow gastric emptying, and reduce appetite. Key Details for Mounjaro 7.5 mg

• Active Ingredient: Tirzepatide (7.5 mg/0.5 mL).
• Mechanism: Dual agonist activating GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors.
• Administration: Once-weekly injection in the abdomen, thigh, or upper arm. It is usually a maintenance dose following a 4-week initiation at 2.5 mg and a 4-week period at 5 mg, depending on patient response.
• Common Side Effects: Nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite.
• Warnings: It carries a warning for potential thyroid C-cell tumors; it should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• Storage: Keep in the refrigerator (2°C to 8°C); can be stored in the pen (not in the refrigerator) for up to 21 days at temperatures below 30°C. 

Additional Information:

• Packaging Details: 1*1

Brand	YURPEAK
Strength	12.5/0.6 ML
Pack Size	1 prefilled pen
Delivery Form	Prefilled Pen
Application	Type 2 Diabetes, Weight Management
Prescription Type	Rx Only
Storage Temperature	2–8°C
Shelf Life	36 months
Usage	Human Use
Country Of Origin	India

Yurpeak 12.5mg KwikPen is a prescription, once-weekly injectable medication containing tirzepatide, used for managing type 2 diabetes 

Additional Information:

• Packaging Details: 1*1